195
Participants
Start Date
May 24, 2016
Primary Completion Date
February 28, 2022
Study Completion Date
April 30, 2031
Letrozole
Tamoxifen
Palbociclib
Endocrine Therapy
Sarah Cannon Research Institute, Nashville
Vanderbilt University Medical Center, Nashville
MD Anderson Cancer Center, Houston
Stamford Hospital, Stamford
Eastern Maine Medical Center, Brewer
Dana-Farber at St. Elizabeth's Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
DF/BWCC at Milford Regional Medical Center, Milford
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth
Lifespan, Providence
Collaborators (1)
Pfizer
INDUSTRY
Dana-Farber Cancer Institute
OTHER